bioAffinity Technologies (Nasdaq: BIAF) teams with Pictor on lung inflammation diagnostics
Rhea-AI Filing Summary
bioAffinity Technologies, Inc. announced a collaboration with Pictor, Inc. to develop and commercialize next-generation diagnostic tests that profile lung inflammation in asthma and COPD by combining bioAffinity’s sputum-based flow cytometry with Pictor’s targeted proteomic platform to analyze immune cell populations and cytokine patterns.
The partners plan to initially offer these diagnostics as Laboratory Developed Tests under CLIA, with bioAffinity owning intellectual property for tests arising from the collaboration and Pictor retaining and expanding IP around its proteomic platform. Asthma and COPD affect more than 40 million Americans and 650 million people worldwide, and the global therapeutics market was valued at approximately $92 billion in 2024 and is projected to exceed $108 billion in 2026 and $155 billion by 2030, illustrating a large potential addressable market. The company notes forward-looking risks related to product development, regulatory changes for LDTs, intellectual property protection, financing needs and realization of anticipated collaboration benefits.
Positive
- None.
Negative
- None.
Insights
Analyzing...
8-K Event Classification
Key Figures
Key Terms
Laboratory Developed Tests (LDTs) regulatory
Clinical Laboratory Improvement Amendments (CLIA) regulatory
targeted proteomic platform technical
flow cytometry technical
cytokines medical
precision medicine medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What collaboration did bioAffinity Technologies (BIAF) announce with Pictor?
How will the new bioAffinity (BIAF) and Pictor asthma and COPD tests work?
What market opportunity does bioAffinity (BIAF) highlight for asthma and COPD diagnostics?
How is intellectual property allocated in the bioAffinity (BIAF)–Pictor collaboration?
What regulatory pathway is planned for bioAffinity (BIAF) asthma and COPD diagnostics?
What key risks does bioAffinity (BIAF) identify for its asthma and COPD test development?
How does the new collaboration relate to bioAffinity (BIAF)’s existing CyPath Lung test?
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification Number) |
(Address of principal executive offices, including zip code)
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e- 4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
| Title of each class | Trading Symbols | Name of each exchange on which registered | ||
|
|
|
(Nasdaq Capital Market) | |
(Nasdaq Capital Market) |
Indicate by check mark whether the registrant is an emerging growth company as defined in in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
If
an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 8.01. Other Events.
On July 22, 2026, bioAffinity Technologies, Inc., a Delaware corporation (the “Company”), issued a press release announcing a collaboration with Pictor, Inc., a targeted proteomic platform company, to support development and commercialization of the Company’s next-generation diagnostic tests designed to provide a more complete picture of lung inflammation in patients with asthma and chronic obstructive pulmonary disease (COPD).
A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
| (d) | Exhibits. |
Exhibit Number |
Description | |
| 99.1 | Press Release issued by bioAffinity Technologies, Inc., dated July 22, 2026 | |
| 104 | Cover Page Interactive Data File (embedded within the XBRL document) |
| -2- |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: July 22, 2026 | BIOAFFINITY TECHNOLOGIES, INC. | |
| By: | /s/ Maria Zannes | |
| Name: | Maria Zannes | |
| Title: | President and Chief Executive Officer | |
| -3- |
Exhibit 99.1
 |
 |
bioAffinity Technologies and Pictor®, Inc. Partner to Develop and Commercialize bioAffinity’s Diagnostics for Asthma and COPD
Collaboration increases laboratory throughput and reduces costs for personalized testing for asthma and COPD, which affect more than 40 million Americans and 650 million people worldwide
Global asthma and COPD therapeutics market projected to exceed $108 billion in 2026 and $155 billion by 2030, driven by increasing use of targeted therapies and biologics
Tests under development are intended to help match asthma and COPD patients with more effective and personalized treatments targeting their specific inflammatory profile
SAN ANTONIO, Texas – July 22, 2026 – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing early-stage cancer diagnostics and targeted therapeutics, today announced a collaboration with Pictor®, Inc., a targeted proteomic platform company, to support development and commercialization of bioAffinity Technologies’ next-generation diagnostic tests designed to provide a more complete picture of lung inflammation in patients with asthma and chronic obstructive pulmonary disease (COPD).
The agreement will integrate bioAffinity’s expertise in flow cytometry with Pictor’s targeted proteomic analysis platform to analyze immune cell populations and cytokine profiles associated with airway inflammation.
“Pictor’s targeted proteomic platform has the ability to lower our operating costs compared with traditional single-analyte testing by improving laboratory efficiency and reducing testing complexity, all of which is required to serve a large and growing market like that of asthma and COPD,” said Maria Zannes, President and CEO of bioAffinity Technologies. “We look forward to taking advantage of Pictor’s expertise in proteomics and product development, and their team’s experience in optimizing laboratory-friendly workflows to facilitate high throughput testing.”
bioAffinity has multiple patents pending for its inventions related to its asthma and COPD testing platform and will own the intellectual property associated with the tests that may emanate from the collaboration. Pictor retains its existing intellectual property and will own new inventions related to its targeted proteomic platform technology.
| -1- |
The tests under development build on bioAffinity’s proprietary approach to interrogating the lung microenvironment through sputum analysis, the same scientific platform that powers CyPath® Lung, the Company’s commercially available noninvasive test that helps physicians assess the likelihood that a pulmonary nodule is malignant. The Company anticipates that the tests under development will initially be offered as Laboratory Developed Tests (LDTs) under the Clinical Laboratory Improvement Amendments (CLIA).
“Asthma and COPD are not single diseases. They encompass multiple inflammatory pathways that require different therapeutic approaches,” said Gordon Downie, MD, PhD, bioAffinity’s Chief Medical Officer. “By measuring immune cell populations using flow cytometry and integrating Pictor’s cytokine profiling platform into its test protocol, our new diagnostics are designed to advance precision medicine in asthma and COPD by providing physicians with a more complete understanding of the biological processes driving airway inflammation in real time.”
bioAffinity Technologies’ flow cytometry platform differentiates and quantifies immune cell populations in sputum while Pictor’s proteomic platform rapidly analyzes the inflammatory proteins, or cytokines, produced by those immune cells. The anticipated result is a high-throughput laboratory test for bioAffinity Technologies that is intended to help physicians identify the inflammatory pathways driving an individual patient’s disease and support more informed decisions when considering advanced therapies, including FDA-approved biologics and emerging targeted treatments.
According to the Centers for Disease Control, asthma and COPD affect more than 40 million Americans and more than 650 million people worldwide, representing a significant potential market for precision diagnostic tools that provide deeper insights into each patient’s disease and help advance personalized treatment. The global asthma and COPD therapeutics market was valued at approximately $92 billion in 2024 and is projected to exceed $108 billion in 2026 and $155 billion by 20301, driven by increasing use of targeted therapies and biologics.
Pictor, Inc. is led by CEO and Managing Director Jamie Platt, PhD, a recognized diagnostics executive who joined bioAffinity Technologies’ Board of Directors in 2023. Prior to her work with Pictor, Dr. Platt helped lead two successful diagnostic company acquisitions valued collectively at nearly $1 billion. Since opening its U.S. headquarters in 2025, Pictor has expanded adoption of its targeted proteomic platform through strategic partnerships across pharmaceutical, laboratory, and research markets.
1 https://www.grandviewresearch.com/industry-analysis/copd-asthma-therapeutics-market-report
| -2- |
“We’re excited to partner with bioAffinity Technologies as they continue to develop innovative, non-invasive tests for lung disease,” said Dr. Jamie Platt, CEO of Pictor. “By combining bioAffinity’s expertise in immune cell biology with Pictor’s scalable proteomic platform, we can advance bioAffinity’s ability to provide insights that move beyond simply identifying disease to understanding the underlying biology of each patient’s condition, leading to more effective treatments.”
Cytokines are small proteins produced by immune and other cells that bind to specific cell receptors to regulate immune responses, inflammation and cell growth. Different patterns of cytokines are associated with different types of asthma and COPD, and many FDA-approved biologic therapies are designed to target specific cytokines or their cellular receptors.
About Pictor, Inc.
Pictor, Inc. is a global targeted proteomic platform company founded in New Zealand and headquartered in Carlsbad, California, with operations in New Zealand, Australia, and India. Pictor’s platform combines PictArray®, PictImager®, and Pictorial© software to support focused, multi-analyte protein analysis for human and animal health research environments. The company works with laboratories, biopharma companies, and other commercial partners to support development of targeted proteomic assays with efficient workflows designed to fit existing laboratory operations. Pictor’s IP portfolio includes 16 patents, five pending, and seven registered trademarks. For more information, visit www.pictorproteomics.com.
About bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. addresses the need for noninvasive diagnosis of early-stage cancer and other diseases of the lung and broad-spectrum cancer treatments. The Company’s first product, CyPath® Lung, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer in clinical studies published in peer-reviewed scientific journals. CyPath® Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies. LDTs are overseen under the Clinical Laboratory Improvement Amendments (CLIA), which are administered by the Centers for Medicare & Medicaid Services. For more information, visit www.bioaffinitytech.com.
Forward-Looking Statements
Certain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend” or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. These forward-looking statements are subject to various risks and uncertainties, many of which are difficult to predict, that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the Company’s ability to successfully develop and commercialize its diagnostic tests for asthma and COPD; the risk that the collaboration with Pictor may not achieve its anticipated benefits or may be terminated; the evolving regulatory landscape for laboratory developed tests, including potential requirements for FDA clearance or approval; the Company’s ability to obtain and maintain adequate intellectual property protection; the Company’s need for additional capital and its ability to obtain financing; the risk that third-party market estimates cited herein may not reflect actual market conditions; the Company’s limited operating history and history of losses; and the other factors discussed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, and its subsequent filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. While the Company believes these forward-looking statements are reasonable, readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The information in this release is provided only as of the date of this release, and the Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.
Contact:
bioAffinity Technologies
Julie Anne Overton
Director of Communications
investors@bioaffinitytech.com
| -3- |